Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mid-America Apartment Communities

162.32
-2.1700-1.32%
Pre-market: 161.81-0.5100-0.31%06:43 EDT
Volume:626.60K
Turnover:101.93M
Market Cap:18.98B
PE:36.19
High:165.20
Open:164.44
Low:161.56
Close:164.49
Loading ...

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire
·
27 Feb

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Business Wire
·
27 Feb

Goldman Sachs Adjusts Price Target on Mid-America Apartment Communities to $187 From $173, Keeps Buy Rating

MT Newswires Live
·
27 Feb

MAA Group Bhd Malaysia 2nd-Quarter 2024 Earnings Summary Table

Dow Jones
·
27 Feb

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

PR Newswire
·
25 Feb

Mid-America Apartment Communities Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
25 Feb

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Business Wire
·
24 Feb

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

CNW Group
·
24 Feb

The Smartest High-Yield Dividend Stocks to Buy With $1,000 Right Now

Motley Fool
·
24 Feb

Is Mid-America Apartment Communities, Inc. (MAA) The Best Self Storage and Apartment Stock to Invest In?

Insider Monkey
·
22 Feb

BNP Paribas Exane Adjusts Mid-America Apartment Communities' Price Target to $163 From $160

MT Newswires Live
·
21 Feb

MAA price target raised to $166 from $159 at Mizuho

TIPRANKS
·
21 Feb

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

GlobeNewswire
·
21 Feb

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

PR Newswire
·
19 Feb

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

GlobeNewswire
·
19 Feb

Mid-America Apartment Is Maintained at Equal-Weight by Barclays

Dow Jones
·
19 Feb